NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 900 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $22.05, for a total value of $19,845.00. Following the completion of the transaction, the chief executive officer now owns 774,190 shares of the company’s stock, valued at $17,070,889.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Asaf Danziger also recently made the following trade(s):

  • On Wednesday, September 13th, Asaf Danziger sold 35,500 shares of NovoCure Limited stock. The stock was sold at an average price of $22.01, for a total value of $781,355.00.
  • On Thursday, September 14th, Asaf Danziger sold 37,272 shares of NovoCure Limited stock. The stock was sold at an average price of $22.01, for a total value of $820,356.72.
  • On Tuesday, July 11th, Asaf Danziger sold 7,383 shares of NovoCure Limited stock. The stock was sold at an average price of $19.95, for a total value of $147,290.85.
  • On Monday, July 10th, Asaf Danziger sold 274,359 shares of NovoCure Limited stock. The stock was sold at an average price of $18.07, for a total value of $4,957,667.13.
  • On Wednesday, July 5th, Asaf Danziger sold 155,088 shares of NovoCure Limited stock. The stock was sold at an average price of $18.14, for a total value of $2,813,296.32.
  • On Thursday, July 6th, Asaf Danziger sold 160,138 shares of NovoCure Limited stock. The stock was sold at an average price of $18.14, for a total value of $2,904,903.32.

NovoCure Limited (NASDAQ NVCR) traded down 5.25% during trading on Friday, hitting $19.85. The stock had a trading volume of 1,691,977 shares. NovoCure Limited has a 12-month low of $5.95 and a 12-month high of $22.30. The firm’s market cap is $1.77 billion. The stock’s 50 day moving average price is $19.72 and its 200 day moving average price is $14.71.

NovoCure Limited (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The firm had revenue of $38.38 million during the quarter, compared to analyst estimates of $42.20 million. NovoCure Limited had a negative return on equity of 69.48% and a negative net margin of 75.91%. On average, analysts anticipate that NovoCure Limited will post ($0.77) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: NovoCure Limited (NVCR) CEO Sells $19,845.00 in Stock” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/insider-selling-novocure-limited-nvcr-ceo-sells-19845-00-in-stock/1598748.html.

Several research firms recently commented on NVCR. Mizuho began coverage on NovoCure Limited in a report on Wednesday, September 6th. They set a “buy” rating and a $25.00 target price on the stock. Zacks Investment Research lowered NovoCure Limited from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub raised NovoCure Limited from a “buy” rating to a “strong-buy” rating in a report on Monday, July 31st. Deutsche Bank AG reissued a “hold” rating and issued a $19.00 price objective (up from $18.00) on shares of NovoCure Limited in a report on Monday, July 17th. Finally, ValuEngine raised NovoCure Limited from a “sell” rating to a “hold” rating in a report on Saturday, June 3rd. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $20.00.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its holdings in shares of NovoCure Limited by 61.7% in the 1st quarter. Bank of America Corp DE now owns 37,531 shares of the medical equipment provider’s stock worth $305,000 after acquiring an additional 14,321 shares during the period. Teachers Advisors LLC grew its holdings in shares of NovoCure Limited by 21.2% in the 4th quarter. Teachers Advisors LLC now owns 95,674 shares of the medical equipment provider’s stock worth $751,000 after acquiring an additional 16,741 shares during the period. River & Mercantile Asset Management LLP grew its holdings in shares of NovoCure Limited by 9.9% in the 2nd quarter. River & Mercantile Asset Management LLP now owns 127,520 shares of the medical equipment provider’s stock worth $2,203,000 after acquiring an additional 11,500 shares during the period. American International Group Inc. grew its holdings in shares of NovoCure Limited by 7.1% in the 1st quarter. American International Group Inc. now owns 31,191 shares of the medical equipment provider’s stock worth $253,000 after acquiring an additional 2,065 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of NovoCure Limited by 1.4% in the 1st quarter. Bank of New York Mellon Corp now owns 173,523 shares of the medical equipment provider’s stock worth $1,406,000 after acquiring an additional 2,480 shares during the period. Institutional investors and hedge funds own 36.84% of the company’s stock.

About NovoCure Limited

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.